Hospital General Universitario Gregorio Marañón-ko ikertzaileekin lankidetzan egindako argitalpenak (66)

2023

  1. Cell-Free DNA Dynamic Concentration and Other Variables Are Predictors of Early Progression after Chimeric Antigen Receptor T Cell Therapy in Patients with Diffuse Large B Cell Lymphoma

    Transplantation and Cellular Therapy, Vol. 29, Núm. 7, pp. 472.e1-472.e4

  2. Decoding the molecular heterogeneity of pediatric monomorphic post–solid organ transplant lymphoproliferative disorders

    Blood, Vol. 142, Núm. 5, pp. 434-445

2022

  1. Correction: EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment (BMC Cancer, (2022), 22, 1, (982), 10.1186/s12885-022-10070-z)

    BMC Cancer

  2. EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment

    BMC Cancer, Vol. 22, Núm. 1

  3. Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications

    Histopathology, Vol. 81, Núm. 6, pp. 826-840

2021

  1. Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide

    Frontiers in Immunology, Vol. 12

  2. Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin’s lymphoma

    Scientific Reports, Vol. 11, Núm. 1

  3. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma

    Nature Communications, Vol. 12, Núm. 1

2020

  1. Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: Progression or divergent evolution?

    PLoS ONE, Vol. 15, Núm. 11 November

2018

  1. Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma

    British Journal of Haematology

2017

  1. Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets

    Oncotarget, Vol. 8, Núm. 67, pp. 111386-111395

2014

  1. Evaluación sistemática de la biopsia de médula ósea en casos de sospecha de mielofibrosis primaria. Propuesta de informe diagnóstico estandarizado. Consenso de expertos de las SEAP/SEHH

    Revista Espanola de Patologia

  2. Hepatitis C virus-related lymphoproliferative disorders encompass a broader clinical and morphological spectrum than previously recognized: A clinicopathological study

    Modern Pathology, Vol. 27, Núm. 2, pp. 281-293

  3. Pathology reporting of bone marrow biopsy in myelofibrosis; application of the Delphi consensus process to the development of a standardised diagnostic report

    Journal of Clinical Pathology, Vol. 67, Núm. 7, pp. 620-625

  4. The RHOA G17V gene mutation occurs frequently in peripheral T-cell lymphoma and is associated with a characteristic molecular signature

    Blood

2013

  1. Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas

    Blood Cancer Journal, Vol. 3, Núm. 4

  2. MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma

    British Journal of Haematology, Vol. 162, Núm. 3, pp. 336-347

  3. Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas

    Haematologica, Vol. 98, Núm. 1, pp. 57-64

  4. Síndrome mieloproliferativo transitorio asociado a síndrome de Down

    Actas Dermo-Sifiliograficas

  5. Timo intratiroideo ectópico como causa de nódulo tiroideo solitario

    Anales de Pediatria